Waterdrop (NYSE:WDH), a leading technology-driven platform dedicated to insurance and healthcare services, reported a robust financial performance for the fourth quarter and full year ended December 31, 2025.
For the fourth quarter of 2025, Waterdrop’s net operating revenue soared to RMB1,411.2 million, marking a 105.5% increase compared to the same period in 2024.
This growth translated effectively to the bottom line, with quarterly net profit attributable to ordinary shareholders reaching RMB162.1 million—a 62.7% year-over-year improvement.
The company’s management attributed this momentum to the aggressive deployment of artificial intelligence across its core business segments.
Key technological milestones cited include the integration of AI within insurance underwriting and a sophisticated fraud control system for its medical crowdfunding platform.
Additionally, the company highlighted its patented intelligent drug-patient matching technology, which has become a primary driver for its digital clinical trial business.
In a move to reward long-term investors, Waterdrop’s Board of Directors approved a cash dividend totaling approximately US$10.8 million.
This follows a substantial capital return through the company’s share repurchase program.
As of year-end 2025, Waterdrop has cumulatively repurchased approximately 60.7 million American Depositary Shares (ADSs), representing a total investment of roughly US$118.1 million.